4:01 PM ET
10-Q
Financial Results
Damora Therapeutics Q3 2026 Results: Net Loss of $32M, Loss Widens
Damora Therapeutics reported a significant increase in operating expenses for the nine months ended September 30, 2026, totaling $102.7 million compared to $9.2 million in the prior year, primarily driven by R&D for candidates DMR-001, DMR-002, and DMR-003. The company ended the period with $528.5 million in cash and marketable securities following a substantial increase in ordinary shares outstanding to 61.9 million.
- Key figure
- Net loss $32M